MIRA Stock Overview
Operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
MIRA Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.19 |
52 Week High | US$5.01 |
52 Week Low | US$0.51 |
Beta | 0 |
11 Month Change | -24.20% |
3 Month Change | -18.49% |
1 Year Change | -24.68% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -83.96% |
Recent News & Updates
Here's Why We're Not Too Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Situation
Nov 19Shareholder Returns
MIRA | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -7.8% | 0.9% | 1.0% |
1Y | -24.7% | 13.4% | 32.4% |
Return vs Industry: MIRA underperformed the US Pharmaceuticals industry which returned 13.4% over the past year.
Return vs Market: MIRA underperformed the US Market which returned 32.4% over the past year.
Price Volatility
MIRA volatility | |
---|---|
MIRA Average Weekly Movement | 16.2% |
Pharmaceuticals Industry Average Movement | 9.9% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 16.5% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MIRA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MIRA's weekly volatility has decreased from 91% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2020 | 5 | Erez Aminov | mirapharmaceuticals.com |
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
MIRA Pharmaceuticals, Inc. Fundamentals Summary
MIRA fundamental statistics | |
---|---|
Market cap | US$19.71m |
Earnings (TTM) | -US$11.24m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.8x
P/E RatioIs MIRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MIRA income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$11.24m |
Earnings | -US$11.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.68 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did MIRA perform over the long term?
See historical performance and comparison